MD/GSK/AISC: 2013: Oncology Clinical and Trans
Post# of 147870
(Total Views: 515)
Posted On: 11/06/2024 6:19:31 AM
MD/GSK/AISC:
2013:
Oncology Clinical and Translational Consortium
** notice MD Anderson
https://www.gsk.com/en-gb/media/press-release...h-centres/
___
Jan. 2020:
https://www.ncc.go.jp/en/information/2020/0820/index.html
___
Jump to this:
The University of Texas MD Anderson Cancer Center and GlaxoSmithKline (GSK) have collaborated on several cancer research projects, including:
Therapeutic antibodies:
MD Anderson and GSK developed and licensed therapeutic antibodies that target the OX40 receptor on T cells. The antibodies promote the immune system's attack on cancer.
Immunotherapy drug:
GSK worked with MD Anderson's Moon Shots Program to develop a new immunotherapy drug and clinical trial.
MD Anderson's Institute for Applied Cancer Science (IACS) has partnered with biopharmaceutical companies to develop drugs.
____
Follow IACS:
The Institute for Applied Cancer Science (IACS) is a collaboration between GlaxoSmithKline (GSK) and the University of Texas MD Anderson Cancer Center. The IACS is a patient-focused research center that aims to develop new small-molecule drugs to treat cancer. The IACS works with a team of scientists and physicians to design drugs that address the most pressing needs of patients.
___
Using this approach, IACS works closely with the Moon Shots® and platforms to advance new targeted therapies to patients quickly, safely and effectively.
https://www.mdanderson.org/cancermoonshots/re...ience.html
___
From White House website:
In February 2022, President Biden announced a reignition of the Cancer Moonshot, with a call to action on cancer screening and early detection.
___
Dr. Palmer:
Recently worked for 2 previous high profile executives from GSK.
Dr. Yam:
MD Anderson / GSK long time Cancer Research consortium.
AICS:
MD/GSK collab also focuses on WH cancer inititive.
ViiV Healthcare is 75% owned by GSK.
Dr. Lataillade joined Cytodyn from ViiV.
Last 20 years his focus was HIV.
He oversees our entire Pipeline.
https://www.cytodyn.com/pipeline
Renowned Dr. Palmer is our MASH.
Renowned Dr. Yam is our TNBC.
Reporting to Dr. Lataillade.
2013:
Oncology Clinical and Translational Consortium
** notice MD Anderson
https://www.gsk.com/en-gb/media/press-release...h-centres/
___
Jan. 2020:
https://www.ncc.go.jp/en/information/2020/0820/index.html
___
Jump to this:
The University of Texas MD Anderson Cancer Center and GlaxoSmithKline (GSK) have collaborated on several cancer research projects, including:
Therapeutic antibodies:
MD Anderson and GSK developed and licensed therapeutic antibodies that target the OX40 receptor on T cells. The antibodies promote the immune system's attack on cancer.
Immunotherapy drug:
GSK worked with MD Anderson's Moon Shots Program to develop a new immunotherapy drug and clinical trial.
MD Anderson's Institute for Applied Cancer Science (IACS) has partnered with biopharmaceutical companies to develop drugs.
____
Follow IACS:
The Institute for Applied Cancer Science (IACS) is a collaboration between GlaxoSmithKline (GSK) and the University of Texas MD Anderson Cancer Center. The IACS is a patient-focused research center that aims to develop new small-molecule drugs to treat cancer. The IACS works with a team of scientists and physicians to design drugs that address the most pressing needs of patients.
___
Using this approach, IACS works closely with the Moon Shots® and platforms to advance new targeted therapies to patients quickly, safely and effectively.
https://www.mdanderson.org/cancermoonshots/re...ience.html
___
From White House website:
In February 2022, President Biden announced a reignition of the Cancer Moonshot, with a call to action on cancer screening and early detection.
___
Dr. Palmer:
Recently worked for 2 previous high profile executives from GSK.
Dr. Yam:
MD Anderson / GSK long time Cancer Research consortium.
AICS:
MD/GSK collab also focuses on WH cancer inititive.
ViiV Healthcare is 75% owned by GSK.
Dr. Lataillade joined Cytodyn from ViiV.
Last 20 years his focus was HIV.
He oversees our entire Pipeline.
https://www.cytodyn.com/pipeline
Renowned Dr. Palmer is our MASH.
Renowned Dr. Yam is our TNBC.
Reporting to Dr. Lataillade.
(7)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼